Turn on more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Sign In
Skip to main content Open accessibility information page
Alert

Due to technical issues, the verification line is currently unavailable. We are working to restore the line and apologize for the inconvenience.


To obtain a CDS verification, please email: CDS@dca.njoag.gov and include the registration number(s) for which you require a verification.


For verifications related to New Jersey Prescription Blanks orders, please email: NJPB@dca.njoag.gov and include the license/registration number(s) for which you require a verification.

Alert
On January 16, 2024, Governor Phil Murphy signed the New Jersey Data Privacy Law, P.L. 2023, c. 266. The law went into effect on January 15, 2025. Please click on this Frequently Asked Questions link to learn more about the new law and your rights under it.
Alert
On January 8, 2024, Governor Murphy signed into law P.L. 2023, c. 237, which, among other things: amended the Contractors’ Business Registration Act (“CBRA,” formerly the “Contractors’ Registration Act”), N.J.S.A. 56:8-136 et seq., and created the “Home Improvement and Home Elevation Contractor Licensing Act,” N.J.S.A. 45:5AAA-1 et seq. For more information on the registration requirements for contractors and businesses under these laws, click here.

Press Release

For Immediate Release:
March 2, 2012

Office of The Attorney General
Jeffrey S. Chiesa, Attorney General

Division of Consumer Affairs
Thomas R. Calcagni, Director


  For Further Information and Media Inquiries:
Jeff Lamm
Neal Buccino
(973) 504-6327

New Jersey Division of Consumer Affairs Orders CVS Pharmacy in Chatham to Provide Information Under Oath, Documentation About Practices and Safeguards Related to Reported Improper Dispensing of Pills

View Order

NEWARK - Moving with alacrity on a matter of public health and safety, the New Jersey Division of Consumer Affairs today issued an Order of the Director requiring CVS officials to provide information under oath, including extensive documentation, about a recent incident in which the CVS pharmacy in Chatham reportedly mixed breast cancer medication in with prescription fluoride tablets meant for children in as many as 50 families, potentially over the course of several weeks.

"We have taken immediate action to determine how many families may have been impacted by this potentially dangerous situation and how we can best address this with the pharmacy to identify those families and prevent any harm to children going forward," said Attorney General Jeffrey S. Chiesa. "We want to get the word out to the public so that we can reach any residents in the area who may have been given the wrong pills."

The Order, signed today by Thomas R. Calcagni, Director of the Division of Consumer Affairs, requires that the corporate holder of the Controlled Dangerous Substances registration for the CVS pharmacy in Chatham, and all other persons with knowledge of the reported incident, appear before him and submit to an inquiry under oath on Friday, March 9, 2012.

The Order further requires that CVS representatives provide certified copies of all communications, complaints, and information pertaining to the incident, including internal communications between the pharmacy and corporate headquarters, investigative documents, and records of corrective actions taken after the incident. The company also is ordered to provide copies of all original prescriptions dispensed for Tamoxifen or 0.5 mg fluoride from December 1, 2011 through March 1, 2012, inventory receipts for both drugs delivered to the pharmacy between those dates, and other documents important to the Division's inquiry.

"When pharmacy customers receive medications other than those prescribed, especially for their children, the public has a clear expectation that regulatory authorities will act quickly to ascertain the facts and the scope of any lapses that may have occurred," said Director Calcagni. "CVS has admitted mistakenly dispensing breast cancer medication in lieu of fluoride tablets intended for children. Public safety implications compel an examination of the safety controls in place, not just for these drugs but for all others including those classified as Controlled Dangerous Substances."

The Division of Consumer Affairs recently reorganized its Enforcement Bureau to be more proactive in its mission to seek out and stop prescription drug abuse and diversion, including inspecting pharmacies to ensure appropriate safeguards are in place. Director Calcagni noted that the Division's Enforcement Bureau, Pharmacy Inspection Section, is investigating this matter.

Parents who believe their child may have ingested the wrong medication are urged to immediately call their child's physician. Concerns about the improper use of medication can also be referred to the New Jersey Poison Information and Education System at 1-800-222-1222. For emergencies, dial 911.

Director Calcagni urged any consumers who believe they were affected by the activities of the CVS in Chatham to call the Division of Consumer Affairs' Consumer Service Center hotline, 800-242-5846 (toll free within New Jersey) or 973-504-6200.

Follow the Division of Consumer Affairs on Facebook , and check our online calendar of upcoming Consumer Outreach events.

 

###

Last Modified: 2/26/2015 4:27 AM